129 Xenon Imaging in Patients Treated With Sotatercept
- Status
- RECRUITING
- Phase
- PHASE2
Clinical Trials Related to Merck Sharp & Dohme LLC
Related studies linked through entity extraction aliases.
ZAP-IT: ZN-c3 + Carboplatin + Pembrolizumab in mTNBC
- Status
- TERMINATED
- Phase
- PHASE1
A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)
- Status
- RECRUITING
- Phase
- PHASE3
Ceftolozane/Tazobactam Versus Meropenem for Febrile Neutropenia on Patients Colonized With or at Risk for Infection With Extended Spectrum Beta Lactamase - Producing Pathogens
- Status
- RECRUITING
- Phase
- PHASE4
Study of Suratadenoturev (OBP-301) in Combination With Pembrolizumab in Esophagogastric Adenocarcinoma
- Status
- RECRUITING
- Phase
- PHASE2
Non Primary HCMV Infection: Natural History and Immune Response
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- N/A
A Study on Tuvusertib (Oral ATR Inhibitor) in Combination With PLX038 (Topo1 Inhibitor) in Patients With Advanced Solid Tumors
- Status
- TERMINATED
- Phase
- PHASE1
A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Comprehensive Connected Cancer Care (C4): Intervention Evaluation
- Status
- RECRUITING
- Phase
- NA
Study of Pembrolizumab Plus Chemotherapy With Lenvatinib for Malignant Pleural Mesothelioma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
- Status
- RECRUITING
- Phase
- PHASE3
A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
- Status
- RECRUITING
- Phase
- PHASE3
A Study of Adjuvant Intismeran Autogene (V940) and Pembrolizumab in Renal Cell Carcinoma (V940-004).
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
A Clinical Study of Intismeran Autogene (V940) Treatment and Pembrolizumab in People With Bladder Cancer (V940-005/INTerpath-005)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
COVIDVaxStories: Randomized Trial to Reduce COVID-19 Vaccine Hesitancy in Populations of Color
- Status
- COMPLETED
- Phase
- NA
A Study of (Neo)Adjuvant Intismeran Autogene (V940) and Pembrolizumab in Cutaneous Squamous Cell Carcinoma (V940-007)
- Status
- TERMINATED
- Phase
- PHASE2/PHASE3
A Study of MK-8527 in Participants With Moderate and Severe Renal Impairment (MK-8527-008)
- Status
- COMPLETED
- Phase
- PHASE1
A Study to Evaluate Antimalarial Activity and Safety of MK-7602 in Healthy Adults (MK-7602-003)
- Status
- COMPLETED
- Phase
- PHASE1
Neuroinflammatory Interactions of ATP and P2X3 Receptor in the Airways of Chronic Cough Patients
- Status
- RECRUITING
- Phase
- N/A